Tcell activation results in a rapid activation of NF-κB ([@B1], [@B2]) which appears to play an important role in T cell proliferation, partly because of the involvement of this transcription factor in the upregulation of the IL-2 and cognate receptor (IL-2R) genes ([@B3]). NF-κB was originally described to be composed of heterodimeric subunits of p50 and p65 proteins ([@B1], [@B2]) and is typically found in the cytoplasm of cells as an inactive precursor complex with an inhibitor protein, IκB ([@B4]). The *NF-κB1* gene product p105 is processed into the DNA-binding subunit of p50 through a mechanism that requires serine phosphorylation ([@B5]) and the induction of an ATP-dependent ubiquitin--proteasome pathway ([@B6], [@B7]). Cellular activation leads to an increase in *NF-κB1* transcripts, p105 processing, and subsequent p50 accumulation in both fibroblasts and in T cells ([@B5], [@B8]).

Although little is known about the regulation of *NFκB1* in T lymphocytes, its expression has been demonstrated to be essential for proliferation after costimulation through CD2 or CD28 receptors ([@B9]). Recently, it has been demonstrated that lymphocytes derived from p50^−/−^-deficient mice display defects in immune responses ([@B10]). In addition Sha et al. ([@B10]) noted that T cells derived from these animals were unable to effectively proliferate in response to TCR and CD28 costimulation. Although disruption of the *NF-κB1* gene did not result in lethality, possibly because *NF-κB2*/p52 could substitute for p50, these studies strongly suggest that the p50 DNA-binding component of NF-κB is critical for T cell proliferation.

Analysis of the *NF-κB1* promoter revealed several NF-κB DNA-binding sites within the upstream regulatory region which are capable of binding p50 homodimers, p50/p65, or p50/c-Rel heterodimers and, in part, account for the ability of NF-κB to regulate *NF-κB1* gene expression ([@B11], [@B12]). Although the *NF-κB1* promoter has been shown to require NF-κB for activity, it is presently unclear whether NF-κB needs other transcription factors to mediate a transcriptional response. This is especially important because on many responsive promoters NF-κB alone is insufficient at activating transcription ([@B2]). T cell stimulation mediated by the addition of either PMA and PHA or TNF-α results in an increase in *NF-κB1* expression ([@B13]). Both stimuli activate NF-κB nuclear translocation and DNA-binding within 15 to 30 min ([@B14]); however, phorbol esters in combination with mitogens result in a greater accumulation of *NF-κB1* transcripts ([@B11], [@B13]). Our research demonstrates that full PMA/PHA-mediated activation of the *NF-κB1* promoter not only required the NF-κB transcription factor, but also the activation of the early growth response gene product (Egr-1)^1^. Egr-1, also known as NGFI-A, Zif268, Krox-24, and Tis 8, is transiently induced during the activation of T cells from the G~0~ to G~1~ phase in response to various cellular stimuli ([@B15]), has been recently demonstrated to be required for T cell proliferation, and is known to regulate transcription of several genes ([@B15]--[@B17]). Our data establishes Egr-1 and RelA as important transcription factors capable of synergistically transactivating the *NF-κB1* promoter.

Materials and Methods
=====================

Cell Culture and Transient Transfection Analysis.
-------------------------------------------------

CEM cells were cultured in RPMI 1640 medium containing 10% FCS and antibiotics. Cells were stimulated by supplementing their growth medium with either PMA and PHA (Sigma Chemical Co., St. Louis, MO) to a final concentration of 50 ng/ml and 5 μg/ml, respectively, or TNF-α (10 ng/ml; Promega Corp., Madison, WI). Transient transfections by electroporation ([@B11]) and luciferase or chloramphenicol acetyl-transferase assays were performed as previously described ([@B11], [@B18], [@B19]).

Plasmid Constructs and Site-directed Mutagenesis.
-------------------------------------------------

Both the *NFκB1* promoter constructs, p50HS- and p50SS-CAT, were previously described ([@B11]). The SpS-, HiS-, and AS-CAT constructs were generated by digesting the p50HS-CAT reporter with HindIII, and SphI, HinfI, or ApoI, respectively. The SSLUC reporter plasmid was generated by cloning the StuI/SmaI fragment from p50HS-CAT into the pGL2 basic reporter containing the luciferase gene (Promega Corp.). The StuI/SmaI fragment of the *NF-κB1* promoter was subjected to site-directed mutagenesis using a two-staged PCR ([@B20]). The mNLUC construct, containing the disrupted 289-bp NF-κB site, was made using a 5′ primer (5′-ATGTAACTGAGACACGCTTAAATGGAATA-3′) and a 3′ primer (5′-AGGCCATCAGCGCCGCGCCATGGCCGCA-3′) in the first round of amplification and two internal primers (5′-AGGCGCTTCCTGGAAGCTTGAATACCGGCTCCAG-3′ and 5′-CTGGAGCCGGTATTCAAGCTTCCAGGAAGCGCCT-3′) which mutated the κB element to a HindIII site. The *NF-κB1* promoter sequences containing a site-directed mutation within the Egr-1 DNA binding site (mELUC) was created using the same 5′ and 3′ primers described above plus two internal primers (5′-GCGCACGCAGCGAATTCGGGAGGTAGGGTC-3′) and (5′-GACCCTACCTCCCGAATTCGCTGCGTGCGC-3′) which destroyed both the SP1/Egr-1 motif and created a unique EcoRI site. The mNELUC construct was created by mixing the mutant Egr-1 oligos described above and using the mNF-κB fragment as a template. The PCR amplified *NF-κB1* promoter fragments were cloned into the SSLUC construct by replacing the wild-type PvuII/SmaI fragment with the corresponding site-directed mutant promoter sequences. Nucleotide sequences of mN, mE, and mNELUC constructs were confirmed by sequence analysis.

Northern Blot and Electrophoresis Mobility Shift Analysis.
----------------------------------------------------------

Total cellular RNA was isolated from CEM cells using the RNeasy total RNA kit (Qiagen, Inc., Chatsworth, CA). Northern blot analysis was performed as previously described ([@B11]). Nuclear extracts were isolated and electrophoresis mobility shift analyses (EMSAs) were performed as previously described ([@B11], [@B18]). Oligonucleotides corresponding to the *NF-κB1* promoter Egr-1 DNA binding site (5′-TCGACTCCCGCCCCCGCTGCG-3′ and 5′-TCGACGCAGCGGGGGCGGGAG-3′) were radiolabeled using α-\[^32^P\]dCTP and the Klenow fragment of DNA polymerase I. For antibody super shift assays and competition experiments, nuclear extracts were preincubated (10 min, room temperature) with either 1 μg of antiserum or with a nonradioactive double stranded oligonucleotide before the addition of the radiolabeled gel shift probe. The mutant Egr-1 probe (annealed 5′-TCGACTCCCGAATTCGCTGCG-3′ and 5′-TCGACGCAGCGAATTCGGGAG-3′) was used in competition assays. The Egr-1--specific antibody (SC No. 189) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA).

Generation of Stable Cell Lines.
--------------------------------

The full-length human Egr-1 cDNA was cloned into the EcoR1 site of the CMV-5 expression vector in the antisense orientation. CEM cells were cotransfected with either CMV-AsEgr-1 or with the CMV-5 control vector in the presence of pcDNA-3.1 Neo (Invitrogen, San Diego, CA). Transfected cells were grown in complete RPMI-1640 medium supplemented with 1.5 mg/ml of Geneticin (GIBCO BRL, Gaithersburg, MD) and resistant clones were isolated. RNase protection assays were performed using the RPA II kit (Ambion, Inc., Austin, TX) to ensure that the CEM/AsEgr-1 cells were expressing the CMV-driven antisense human *Egr*-*1* transcript.

Results and Discussion
======================

Differential Expression of NF-κB1 mRNA After PMA/ PHA-- or TNF-α--Stimulation.
------------------------------------------------------------------------------

To determine whether differential expression of *NF-κB1* mRNA was observed after stimulation by PMA and PHA or TNF-α, Northern blot analysis was performed on total cellular RNA isolated from the human T cell line, CEM. As shown in Fig. [1](#F1){ref-type="fig"} *A*, *NFκB1* mRNA began to accumulate within 1 h of stimulation with PMA and PHA, and by 4 h a significant induction (10-fold) was observed in CEM cells. Although TNF-α--stimulated cells also displayed increases in *NF-κB1* transcripts with similar kinetics, a substantially lower accumulation of mRNA was observed over the 4-h time course.

Identification of the NF-κB1 Promoter Region Required for PMA/PHA-Responsive Upregulation.
------------------------------------------------------------------------------------------

To determine whether the increase in *NF-κB1* mRNA, seen in Fig. [1](#F1){ref-type="fig"} *A*, was due to transcriptional upregulation of the promoter and not due to PMA/PHA-induced message stabilization, CEM cells were transiently transfected with the p50HS-CAT *NF-κB1* promoter construct and stimulated with either PMA/PHA or TNF-α for 24 h. As shown in Fig. [1](#F1){ref-type="fig"} *B*, the *NF-κB1* promoter (p50HS-CAT) was strongly activated in CEM cells after PMA/PHA stimulation, but only weakly after TNF-α addition, suggesting that PMA/PHA-mediated activation of the *NF-κB1* promoter was through a transcription-dependent mechanism.

To localize the PMA/PHA-responsive region within the *NF-κB1* promoter, a series of deletion promoter constructs were made. CEM cells were transiently transfected with each reporter construct and then either stimulated with PMA/PHA or with TNF-α. As shown in Fig. [1](#F1){ref-type="fig"} *B*, no significant difference in stimulation was observed between the HS-, the SS-, or the SpS-CAT constructs. However, the HiS-CAT reporter, which lacked the −289 NF-κB site, displayed a significant decrease in *NF-κB1* promoter activity after stimulation by either PMA/PHA or TNF-α. The AS-CAT reporter, lacking both the −103 and −11 κB sites, was greatly diminished in response to PMA/PHA-- and TNF-α--mediated activation (Fig. [1](#F1){ref-type="fig"} *B*). Collectively, this data indicates that the region between the SphI site (−425) and the ApoI site (−9) was critical for both inducers, but that PMA/PHA stimulation resulted in a higher fold activation than TNF-α. Based on the deletion analysis of the *NF-κB1* promoter, these results suggest that both stimuli may use NF-κB, but that the PMA/PHA stimulation must activate additional transcription factors not induced by TNF-α.

The NF-κB1 Promoter Contains an Egr-1 Consensus Site and T Cells Stimulated with PMA and PHA, but not TNF-α, Display Egr-1 DNA Binding.
---------------------------------------------------------------------------------------------------------------------------------------

Computer analysis of the SphI/ApoI fragment of the *NF-κB1* promoter identified potential DNA-binding motifs for five different transcription factors including AP-1, E2F, Egr-1, NF-κB, and SP1. Of these, NF-κB, Egr-1, and AP-1 are known to display increased transactivation potential after PMA stimulation ([@B2], [@B15], [@B21]). Since PMA/PHA and TNF-α both activated NF-κB, we excluded this transcription factor as the nuclear factor responsible for differentially regulating the *NF-κB1* promoter. In addition, the putative AP-1 site located in the *NF-κB1* promoter was not found to affect PMA-induced transactivation of the *NF-κB1* promoter ([@B12]). To test whether extracts from PMA/PHA-stimulated cells would display Egr-1 binding, EMSAs were performed. As shown in Fig. [2](#F2){ref-type="fig"} *A*, a ^32^P double stranded oligonucleotide probe corresponding to the 68-bp Egr-1 site within the *NF-κB1* promoter bound a nuclear protein which was present in PMA/PHA-stimulated cell extracts (lane *2*), but not in unstimulated cell extracts (lane *1*). This DNA--protein complex could also be competed with an excess of wild-type unlabeled oligonucleotide (lane *3*), but not by equal concentrations of a corresponding mutant Egr-1 site (lane *4*). Moreover, this complex contained Egr-1 protein since incubation with an Egr-1--specific antibody completely supershifted the nuclear protein bound to the ^32^P-probe (lane *5*). Pretreatment with cycloheximide, which has been previously demonstrated to block PMA-mediated increases in Egr-1 protein ([@B15]), prevented the detection of Egr-1--specific binding (lane *6*). Although we do not effectively detect SP1 binding under our EMSA conditions (Fig. [2](#F2){ref-type="fig"} *A*), we observed constitutive SP1 binding in nuclear extracts isolated from CEM cells using a modified binding protocol (data not shown). Since SP1 binding to the −68 site was constitutive and completely independent of cellular stimulation mediated by either PMA/ PHA or TNF-α (data not shown), we chose to focus on the inducible binding of the Egr-1 transcription factor.

To elucidate whether differential Egr-1 binding was observed in T cells after the addition of either PMA/PHA or TNF-α, nuclear proteins were isolated from stimulated CEM cells over a 4 h time course and EMSAs were performed using the *NF-κB1* Egr-1 consensus site. After stimulation with PMA/PHA, Egr-1 binding begins to appear within 30 min and continues to increase at both 1 and 2 h with a slight decrease seen at 4 h (Fig. [2](#F2){ref-type="fig"} *B*). Interestingly, no Egr-1 binding was observed in CEM cell extracts after TNF-α stimulation (Fig. [2](#F2){ref-type="fig"} *B*). However, both PMA/ PHA-- and TNF-α--stimulated CEM cells demonstrated NF-κB--specific binding after the addition of each inducer, confirming that CEM cells were capable of responding to TNF-α (data not shown). Identical results to those obtained in the CEM cell line were demonstrated in Jurkat T cells (data not shown). Collectively, these results indicate that the −68 site located in the *NF-κB1* promoter is capable of binding the Egr-1 transcription factor and that, unlike PMA/PHA stimulation, TNF-α fails to stimulate Egr-1 binding in T cell lines.

Efficient PMA/PHA-Responsive Activation of the NF-κB1 Promoter Requires the Egr-1 DNA Binding Site.
---------------------------------------------------------------------------------------------------

To determine whether Egr-1 is required for PMA/PHA responsive activation of the *NF-κB1* promoter, site-directed mutagenesis was performed. Since the *NF-κB1* promoter is regulated directly by NF-κB ([@B11], [@B12]), we chose to mutate the −289 κB motif alone or in combination with the −68 Egr-1 binding site. The four luciferase *NF-κB1* promoter constructs included (*a*) SSLUC, the wild-type construct, (*b*) mNLUC, which contained a mutated NF-κB site at position −289, (*c*) mELUC, which contained the disrupted 68-bp Egr-1 site, and (*d* ) mNELUC, which contained mutated NF-κB and Egr-1 sites. As shown in Fig. [3](#F3){ref-type="fig"} *A*, site-directed mutagenesis of the Egr-1 binding element (mELUC) significantly diminished PMA/PHA-responsive activation of the *NF-κB1* promoter, but had very little or no effect on TNF-α--mediated stimulation. In contrast, mutating the NF-κB −289 site alone had very little effect on either PMA/PHA-- or TNF-α--induced activation (data not shown). These results in conjunction with the promoter deletion studies (shown in Fig. [1](#F1){ref-type="fig"} *B*) would strongly suggest that other κB binding sites (namely −103 and −11) are important for transcriptional activation. Recently, McElhinny et al. ([@B22]) demonstrated that the −11 NF-κB site was required for HIV-mediated induction of *NF-κB1* promoter in monocytes. Although the −289 motif is probably not the only functional NF-κB motif, site-directed mutagenesis of both the Egr-1 and NF-κB elements (mNELUC), resulted in a further decrease in PMA/PHA-responsive stimulation compared to the mELUC construct (Fig. [3](#F3){ref-type="fig"} *A*). Taking into account that mutagenesis of the Egr-1 site in the *NF-κB1* promoter significantly diminished PMA/PHA-responsive stimulation, these results indicate that the −68 Egr-1 site plays an important role in the activation of this gene in T lymphocytes.

NF-κB and Egr-1 Transcription Factors Synergistically Transactivate the NF-κB1 Promoter.
----------------------------------------------------------------------------------------

To further explore the ability of each of these transcription factors to activate the *NFκB1* promoter, the wild-type as well as the site-directed mutant reporters were cotransfected with the empty expression plasmid or with constructs encoding either RelA, the p65 subunit of NF-κB, Egr-1, or a combination of both. As shown in Fig. [3](#F3){ref-type="fig"} *B*, the SSLUC reporter was strongly transactivated after cotransfection with the RelA encoding expression construct, but only weakly activated by the overexpression of Egr-1. Interestingly, transfection with both RelA and Egr-1 resulted in a potent synergistic transactivation of the *NF-κB1* promoter. Although the −289 κB site was important for RelA-mediated transactivation, mutagenesis of this element did not affect activation by Egr-1, nor did it affect RelA/Egr-1 synergy (Fig. [3](#F3){ref-type="fig"} *B*). This result would suggest that, in the presence of Egr-1 binding, other κB sites located within the *NF-κB1* promoter are used for the synergistic response. Unlike the mNLUC reporter, mutagenesis of the Egr-1 site (mELUC) resulted in a significant reduction in RelA-, Egr1-, and RelA/Egr1mediated activation of the *NF-κB1* promoter (Fig. [3](#F3){ref-type="fig"} *B*). However, disruption of both the −289 and −68 sites (mNELUC) did not further diminish RelA/Egr-1--mediated synergy. This would suggest that overexpression of both of these transcription factors may indirectly lead to the activation of the *NF-κB1* promoter by upregulating other *trans*-acting elements, or that Egr-1 (like NF-κB) recognizes other DNA-binding sites within the *NF-κB1* promoter. Collectively, co-transfection studies strongly suggest that the Egr-1 DNA binding site is critical for both Egr1--mediated transactivation and for RelA/Egr-1-dependent synergy. Although the Rel homology domain of RelA has been shown to be responsible for protein--protein interactions with transcription factors outside of the NF-κB/Rel family ([@B23]--[@B26]), we were unable to demonstrate a physical interaction between RelA and Egr-1, nor were we able to generate synergistic transactivation mediated by these factors using either a 3×--NF-κB or 3×-Egr-1 CAT reporter (data not shown).

Egr-1 Complements TNF-α to Stimulate the NF-κB1 Promoter.
---------------------------------------------------------

To determine whether the difference between PMA/ PHA-- and TNF-α--stimulated *NF-κB1* gene expression was due to the inability of TNF-α to activate Egr-1, CEM cells were transfected with the SSLUC reporter along with the empty vector control or with the Egr-1 expression construct and 24 h later cells were stimulated with PMA/PHA or TNF-α. As shown in Fig. [3](#F3){ref-type="fig"} *C*, the fold increase between cells transfected with the vector control or with the Egr-1 expression construct was comparable to previous experiments, while PMA/PHA-stimulated cells (coexpressing Egr-1) displayed the highest level of *NF-κB1* activation. Interestingly, cells transfected with Egr-1 and stimulated with TNF-α displayed a significant increase in promoter activity, compared to TNF-α--stimulated cells transfected with the vector control. The ability of Egr-1 to augment TNF-α--mediated activation of the *NF-κB1* promoter was a direct effect since the transcriptional synergy was not observed with the mELUC construct containing the disrupted Egr-1 binding site (data not shown). These results demonstrate that the Egr-1 transcription factor can complement TNF-α--mediated stimulation of the *NF-κB1* promoter. Furthermore, our data suggests that the inability of TNF-α to activate Egr-1 may account for the difference between PMA/PHA-- and TNF-α--mediated *NF-κB1* gene expression in T cells.

Endogenous NF-κB1 Gene Expression Is Affected in T Cells Expressing Antisense Egr-1 RNA.
----------------------------------------------------------------------------------------

To determine the importance of the Egr-1 transcription factor on endogenous *NF-κB1* gene expression, we developed a CEM cell line which constitutively expressed antisense human Egr-1 RNA. Total RNAs were isolated from either CEM/AsEgr-1 cells (which express the human Egr-1 antisense RNA) or from CEM/CMV control cells (which harbor the empty expression vector) after the addition of either PMA/PHA or TNF-α over the time course indicated. As shown in Fig. [4](#F4){ref-type="fig"} *A*, CEM/AsEgr-1 cells did not display significant increases in *NF-κB1* transcripts until 4 h after PMA/PHA addition, while the control cells (CEM/CMV) responded within 1 to 2 h with similar kinetics as the parental CEM cell line (Fig. [1](#F1){ref-type="fig"} *A*). Interestingly, TNF-α--stimulated CEM/ AsEgr-1 cells demonstrated a reduction in *NF-κB1* transcripts 30 min after activation. Although TNF-α does not activate Egr-1, it would appear that under conditions in which endogenous Egr-1 levels are reduced (as with CEM/ AsEgr-1 cells), TNF-α stimulation represses *NF-κB1* transcription (Fig. [4](#F4){ref-type="fig"} *A*). Although the level of Egr-1 protein in the CEM/AsEgr-1 cells after PMA/PHA stimulation was significantly lower (fivefold) than protein levels observed in the control line, the antisense Egr-1 transcripts were not able to completely block PMA/PHA-mediated increases in Egr-1 protein (Fig. [4](#F4){ref-type="fig"} *B*). Perhaps for this reason CEM/ AsEgr-1 cells are still able to display PMA/PHA-responsive upregulation of *NF-κB1* transcripts but with slower kinetics.

In this paper we have demonstrated that to achieve full activation of the *NF-κB1* promoter, T cell signals require not only the activation of NF-κB, but also the Egr-1 transcription factor. Interestingly, it appears that the potent activation of NF-κB DNA binding activity by TNF-α is insufficient at inducing high levels of *NF-κB1* transcription. This is consistent with the recent report that activation of NF-κB binding by TNF-α is insufficient at activating VCAM-1 transcription in some cells, but the co-activation of NF-κB and IRF-1 in endothelial cells functions to stimulate transcription ([@B27], [@B28]). Moreover, like NF-κB, Egr-1 is a relatively poor activator of *NF-κB1* transcription. Thus, it is the combined action of NF-κB and Egr-1, both of which alone result in weak activation, that functions to synergistically stimulate the *NF-κB1* promoter. A number of NFκBresponsive genes have been characterized and found to require Egr-1 DNA binding motifs for maximum transactivation. Such genes include TNF-α, IL-2, and ICAM-1 ([@B17], [@B29], [@B30]). In T cells, TNF-α does not fully upregulate its own promoter, presumably because of the inability of cytokines to activate Egr-1 ([@B17]). However, primary human fibroblasts and macrophage cell lines display dramatic increases in Egr-1 after TNF-α stimulation ([@B15]). Collectively, these studies would suggest that the synergistic potential mediated by the NFκB and Egr-1 transcription factors are not only restricted by the type of stimuli, but also may depend on the particular cell type. Thus, it appears that the functional interaction of NF-κB and Egr-1 in the context of a promoter is likely to mediate critical aspects of T cell signaling and potentially other important aspects of cellular growth control. The potent synergy between NF-κB and Egr-1 may explain, at least partially, the requirements for these transcription factors in T cell proliferation with *NF-κB1* being a critical downstream target for Egr-1.
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###### 

*NF-κB1* gene expression and promoter analysis in CEM cells after PMA/ PHA or TNF-α stimulation. (*A*) RNAs were isolated from CEM cells after addition of either PMA/PHA (50 ng and 5 μg/ml) or TNF-α (10 ng/ml) over the time course indicated. RNAs were detected using a ^32^Plabeled *NF-κB1*-specific probe. Transcripts encoding *NF-κB1* were quantitated by densitometric scanning of autoradiograms and the fold accumulation of mRNAs were calculated after normalization to β-actin. (*B*) Schematic of the *NF-κB1* promoter depicting the Egr-1 and NF-κB binding sites. CEM cells were transfected with either the HS-CAT reporter or with various deletion constructs (SS-, SpS-, HiS-, and AS-CAT). 18 h after transfection, cells were stimulated with either PMA/PHA (50 ng and 5 μg/ ml) or TNF-α (10 ng/ml) and CAT activity was analyzed. Transfection experiments were performed in triplicate and the mean fold induction and the standard deviations are shown.
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###### 

Identification of an Egr-1 DNA binding site within the *NFκB1* promoter. (*A*) Nuclear extracts were isolated from CEM cells after a 2 h PMA/PHA stimulation in either the absence or presence of cycloheximide (50 μg/ml, 30 min pretreatment). Nuclear extracts (5 μg) were incubated with a ^32^P-labeled probe corresponding to the 68-bp Egr-1 site. Competition assays and antibody supershift experiments were performed by preincubating nuclear extracts (15 min) with either unlabeled mutant Egr-1 (mEgr-1) or wild-type Egr-1 oligonucleotide (50 ng total) before the addition of probe. Lane *1*, unstimulated cells; lane *2,* PMA/PHA for 2 h; lane *3,* PMA/PHA + wild-type Egr-1 oligo; lane *4,* PMA/PHA + mEgr-1 oligo; lane *5*, PMA/PHA + Egr-1--specific antibody; lane *6*, pretreatment with cycloheximide (30 min) + PMA/PHA for 2 h. *SS* indicates the position of the Egr-1 + antibody supershift complex; *NS* identifies nonspecific bands. (*B*) Nuclear proteins from CEM cells were isolated after the addition of either PMA/PHA or TNF-α over the indicated time course and EMSAs were performed using the ^32^P-labeled Egr-1 site. Note that the unbound ^32^P-labeled probe is not shown in both *A* and *B.*
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###### 

The Egr-1 DNA binding site is required for PMA/PHA--responsive activation and for transcriptional synergy mediated by RelA and Egr-1. (*A*) CEM cells were transfected with either the wild-type *NF-κB1* promoter (SSLUC) or with each of the site-directed mutants including (*a*) mNLUC, which contained a mutated NF-κB site at position −289, (*b*) mELUC, which contained a disrupted 68-bp Egr-1 site, and (*c*) mNELUC, which contained mutated NF-κB and Egr-1 sites, and 18 h later cells were stimulated with either PMA/PHA or TNF-α. 24 h after stimulation, cell extracts were harvested and assayed for luciferase activity. (*B*) CEM cells were co-transfected with either the SSLUC construct or with mutant reporters (mN, ME, mNE; 5 μg each) and with various expression vectors (5 μg) including an empty vector control, RelA, Egr-1, or RelA plus Egr-1. Cells were harvested 48 h after transfection and luciferase activities were determined. (*C*) The SSLUC construct was transfected into CEM cells along with either the vector control or with an Egr-1 expression construct. 18 h after transfection, cells were either left untreated or stimulated with PMA/PHA or TNF-α. Cells were harvested 24 h after stimulation and extracts were analyzed for luciferase activity. All transfection assays were performed in triplicate in three independent experiments.
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###### 

Egr-1 is required for endogenous *NF-κB1* gene expression. (*A*) Total RNAs were isolated from CEM/CMV control cells or from CEM/AsEgr-1 cells stimulated with either PMA/PHA or TNF-α over a 4 h period. RNAs were detected using a ^32^P-labeled *NF-κB1* specific probe. (*B*) Total proteins were isolated from CEM/CMV or CEM/AsEgr-1 cells after the addition of either PMA/PHA or TNF-α. Proteins were subjected to PAGE and analyzed using an Egr-1--specific antibody and enhanced chemiluminescent assay. *NS,* shows the presence of a nonspecific band and demonstrates that equal amounts of protein were loaded in each lane.
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